Secondary Prevention of Venous Thrombo Embolism (VTE).
Public ClinicalTrials.gov record NCT00329238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.
Study identification
- NCT ID
- NCT00329238
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,867 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Sep 30, 2010
- Completion
- Not listed
- Last update posted
- May 18, 2014
Started 2006
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1160.47.01035 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1160.47.01056 Boehringer Ingelheim Investigational Site | Hartford | Connecticut | — | — |
| 1160.47.01044 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1160.47.01019 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 1160.47.01008 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1160.47.01014 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1160.47.01018 Boehringer Ingelheim Investigational Site | Roxbury Crossing | Massachusetts | — | — |
| 1160.47.01023 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 1160.47.01009 Boehringer Ingelheim Investigational Site | Saint Louis Park | Minnesota | — | — |
| 1160.47.01031 Boehringer Ingelheim Investigational Site | Lebanon | New Hampshire | — | — |
| 1160.47.01036 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1160.47.01027 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 1160.47.01039 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1160.47.01030 Boehringer Ingelheim Investigational Site | Grand Forks | North Dakota | — | — |
| 1160.47.01013 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1160.47.01052 Boehringer Ingelheim Investigational Site | Altoona | Pennsylvania | — | — |
| 1160.47.01055 Boehringer Ingelheim Investigational Site | Summerville | South Carolina | — | — |
| 1160.47.01017 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 257 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00329238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2014 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00329238 live on ClinicalTrials.gov.